Piper Jaffray’s healthcare analyst Charles Duncan is weighing in today on biotech companies CTI BioPharma Corp (NASDAQ:CTIC) and BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), as shares …
In a research report released today, H.C.
In a research note published yesterday, Roth Capital analyst Debjit Chattopadhyay reiterated coverage with a Buy rating on shares of CTI Biophrarma Corp. (CTIC) …
In a report released Tuesday, Roth Capital analyst Debjit Chattopadhyay reiterated coverage on CTI BioPharma Corp (CTIC) with a Buy rating and a $4.00 price target, following yesterday’s news …
In a research report released Tuesday, HC Wainwright analyst Reni Benjamin reiterated a Buy rating on CTI BioPharma Corp (CTIC) with a price target of $6.00 following the completion of …
In a research note issued this morning, H.C.
